Literature DB >> 23872831

CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.

M J Ratain1, Y Nakamura, N J Cox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23872831      PMCID： PMC3782290          DOI： 10.1038/clpt.2013.66

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  10 in total

1.  CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.

Authors:  Werner Schroth; Ute Hamann; Peter A Fasching; Silke Dauser; Stefan Winter; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Journal:  Clin Cancer Res       Date:  2010-06-01       Impact factor: 12.531

2.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

3.  Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.

Authors:  Kazuma Kiyotani; Taisei Mushiroda; Naoya Hosono; Tatsuhiko Tsunoda; Michiaki Kubo; Fuminori Aki; Yutaka Okazaki; Koichi Hirata; Yuichi Takatsuka; Minoru Okazaki; Shozo Ohsumi; Takashi Yamakawa; Mitsunori Sasa; Yusuke Nakamura; Hitoshi Zembutsu
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

4.  Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.

Authors:  William J Irvin; Christine M Walko; Karen E Weck; Joseph G Ibrahim; Wing K Chiu; E Claire Dees; Susan G Moore; Oludamilola A Olajide; Mark L Graham; Sean T Canale; Rachel E Raab; Steven W Corso; Jeffrey M Peppercorn; Steven M Anderson; Kenneth J Friedman; Evan T Ogburn; Zeruesenay Desta; David A Flockhart; Howard L McLeod; James P Evans; Lisa A Carey
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

5.  Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.

Authors:  Anne-Joy M de Graan; Sebastiaan F Teunissen; Filip Y F L de Vos; Walter J Loos; Ron H N van Schaik; Felix E de Jongh; Aad I de Vos; Robbert J van Alphen; Bronno van der Holt; Jaap Verweij; Caroline Seynaeve; Jos H Beijnen; Ron H J Mathijssen
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

6.  Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Authors:  L Madlensky; L Natarajan; S Tchu; M Pu; J Mortimer; S W Flatt; D M Nikoloff; G Hillman; M R Fontecha; H J Lawrence; B A Parker; A H B Wu; J P Pierce
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

7.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.

Authors:  Jean E Abraham; Mel J Maranian; Kristy E Driver; Radka Platte; Bolot Kalmyrzaev; Caroline Baynes; Craig Luccarini; Mitul Shah; Susan Ingle; David Greenberg; Helena M Earl; Alison M Dunning; Paul D P Pharoah; Carlos Caldas
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

8.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Authors:  Werner Schroth; Matthew P Goetz; Ute Hamann; Peter A Fasching; Marcus Schmidt; Stefan Winter; Peter Fritz; Wolfgang Simon; Vera J Suman; Matthew M Ames; Stephanie L Safgren; Mary J Kuffel; Hans Ulrich Ulmer; Julia Boländer; Reiner Strick; Matthias W Beckmann; Heinz Koelbl; Richard M Weinshilboum; James N Ingle; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Journal:  JAMA       Date:  2009-10-07       Impact factor: 56.272

9.  Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.

Authors:  Wendy Lorizio; Hope Rugo; Mary S Beattie; Simone Tchu; Teri Melese; Michelle Melisko; Alan Hb Wu; H Jeffrey Lawrence; Michele Nikoloff; Elad Ziv
Journal:  Genome Med       Date:  2011-10-04       Impact factor: 11.117

Review 10.  Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy.

Authors:  Elaine Lyon; Julie Gastier Foster; Glenn E Palomaki; Victoria M Pratt; Kristen Reynolds; M Fernanda Sábato; Stuart A Scott; Patrik Vitazka
Journal:  Genet Med       Date:  2012-09-06       Impact factor: 8.822
  10 in total
  22 in total

1.  CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Authors:  D L Hertz; K M Kidwell; S G Hilsenbeck; S Oesterreich; C K Osborne; S Philips; C Chenault; R J Hartmaier; T C Skaar; M J Sikora; J M Rae
Journal:  Breast Cancer Res Treat       Date:  2017-07-20       Impact factor: 4.872

2.  CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.

Authors:  Hiltrud Brauch; Matthias Schwab
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

3.  Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

Review 4.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 5.  Pharmacogenomics in the clinic.

Authors:  Mary V Relling; William E Evans
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

6.  Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.

Authors:  Lena Klopp-Schulze; Markus Joerger; Sebastian G Wicha; Rob Ter Heine; Chantal Csajka; Zinnia P Parra-Guillen; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

7.  Genomic medicine, precision medicine, personalized medicine: what's in a name?

Authors:  D M Roden; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2013-08       Impact factor: 6.875

Review 8.  CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.

Authors:  M P Goetz; J N Ingle
Journal:  Clin Pharmacol Ther       Date:  2014-08       Impact factor: 6.875

Review 9.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

10.  Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups.

Authors:  Anna Mueller-Schoell; Robin Michelet; Lena Klopp-Schulze; Madelé van Dyk; Thomas E Mürdter; Matthias Schwab; Markus Joerger; Wilhelm Huisinga; Gerd Mikus; Charlotte Kloft
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.